Thorsten Raff

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp, Peter Kufer, Nicola Gökbuget et al. · Journal of Clinical Oncology · 2011 · 902 citations · Full text

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data

Vincent H. J. van der Velden, Giovanni Cazzaniga, André Schrauder et al. · Leukemia · 2007 · 694 citations · Full text

Genetics, Genetic Epidemiology, Pathology +16

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

Monika Brüggemann, Thorsten Raff, Thomas Flohr et al. · Blood · 2005 · 534 citations

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

Nicola Gökbuget, Michael Kneba, Thorsten Raff et al. · Blood · 2012 · 486 citations

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier et al. · Blood · 2012 · 466 citations · Full text